These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31703581)

  • 21. The Relationship between Acidic Urinary pH and Overactive Bladder; Alkalization of Urine Improves the Symptoms of Overactive Bladder.
    Demirbas A; Sarici H; Kilinc MF; Telli O; Ozgur BC; Doluoglu OG; Bozkurt S
    Urol Int; 2015; 95(2):223-6. PubMed ID: 25766740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects.
    Hsiao SM; Su TC; Chen CH; Chang TC; Lin HH
    Maturitas; 2014 Sep; 79(1):65-9. PubMed ID: 25022469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of overactive bladder and nocturia as a risk factor for hip fracture in climacteric women: a matched pair case control study.
    Karabulut A; Simavlı S; Demirtaş Ö; Ök N; Güngör HR; Zümrütbaş A
    J Obstet Gynaecol; 2018 Feb; 38(2):252-256. PubMed ID: 28903631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coffee intake, health-related quality of life, and associated factors of overactive bladder in older Korean women living in rural South Korea.
    Park J; Lee YJ; Lee K; Park S
    J Women Aging; 2019; 31(5):367-380. PubMed ID: 29528788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravesical electrical stimulation treatment for overactive bladder: An observational study.
    Yune JJ; Shen JK; Pierce MA; Hardesty JS; Kim J; Siddighi S
    Investig Clin Urol; 2018 Jul; 59(4):246-251. PubMed ID: 29984339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The influence of mesh pelvic floor reconstructive surgery on OAB symptoms].
    Nowakowski L; Wróbel A; Jankiewicz K; Kulik-Rechberger B; Rechberger T
    Ginekol Pol; 2014 Oct; 85(10):760-4. PubMed ID: 25546927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study.
    Lee KS; Yoo TK; Liao L; Wang J; Chuang YC; Liu SP; Chu R; Sumarsono B
    BMC Urol; 2017 Nov; 17(1):108. PubMed ID: 29162085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of biofeedback therapy in children with treatment-refractory dysfunctional voiding and overactive bladder.
    Tugtepe H; Thomas DT; Ergun R; Abdullayev T; Kastarli C; Kaynak A; Dagli TE
    Urology; 2015 Apr; 85(4):900-4. PubMed ID: 25669732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Solifenacin may improve sleep quality in patients with overactive bladder and sleep disturbance.
    Takao T; Tsujimura A; Yamamoto K; Fukuhara S; Nakayama J; Matsuoka Y; Miyagawa Y; Nonomura N
    Urology; 2011 Sep; 78(3):648-52. PubMed ID: 21676440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder.
    Nik-Ahd F; Lenore Ackerman A; Anger J
    Curr Urol Rep; 2018 Sep; 19(11):94. PubMed ID: 30215140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Bladder Training and Pelvic Floor Muscle Training in Female Patients with Overactive Bladder Syndrome: A Randomized Controlled Trial.
    Rizvi RM; Chughtai NG; Kapadia N
    Urol Int; 2018; 100(4):420-427. PubMed ID: 29672306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overactive Bladder Symptoms in Female Health Profession Students: Bladder Diary Characteristics and Impact of Symptoms on Health-Related Quality of Life.
    Reisch R; Rutt R; Dockter M; Sanders S
    J Womens Health (Larchmt); 2018 Feb; 27(2):156-161. PubMed ID: 28953429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle.
    Dokmeci F; Cetinkaya SE; Seval MM; Dai O
    Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*.
    Herschorn S; Heesakkers J; Castro-Diaz D; Wang JT; Brodsky M; Guan Z;
    Curr Med Res Opin; 2008 Dec; 24(12):3513-21. PubMed ID: 19032133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1-9 V) during Stage 1 sacral neuromodulation.
    Marinkovic SP; Ford JC
    BJU Int; 2018 Sep; 122(3):472-479. PubMed ID: 29637712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.